Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
| Status: | Archived |
|---|---|
| Conditions: | Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters
This study examines the difference in the effectiveness of two natural compounds,
eicosapentanoic (EPA) and docosahexanoic (DHA)omega-3 fatty acids, in treating major
depressive disorder. Both types of omega-3 fatty acids are commonly found in fish oils. It
is believed that a deficiency in these omega-3 fatty acids may lead to the development of
major depression.
The study lasts for eight weeks and involves four visits after the screen and baseline
visits (biweekly). Participants will be randomized, or chosen by chance, to enter into one
of three groups. People in the first group will take 1 g/day or EPA omega-3 fatty acid,
those in the second group will take 1 g/day of DHA omega-3 fatty acid, and those in the
third group will take a placebo. This study is double-blind, which means that neither the
participant, nor the doctor, nor the research staff will know which group each person is in.
At the end of the study the participant will be offered three months of follow-up care at
the Depression Clinical and Research Program.
We found this trial at
1
site
Boston, Massachusetts 02114
Click here to add this to my saved trials
